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A simple and sensitive HPLC method was developed and validated for the quantification of haloperidol 
in solid lipid nanoparticles (SLNs). The developed method was used for detection of shelf life of 
haloperidol in SLNs. Calibration curve of haloperidol was also constructed in rat plasma using loratidine 
as internal standard. In vivo studies were performed on rats and concentration of haloperidol in brain 
and blood was measured for the determination of various pharmacokinetic and hence brain targeting 
parameters. Chromatogram separation was achieved using C18 column as stationary phase. The mobile 
phase consisted of 100 mM/L potassium dihydrogen phosphate–acetonitrile–TEA (10:90:0.1, v/v/v) 
and the pH was adjusted with o-phosphoric acid to 3.5. Flow rate of mobile phase was 2 mL/minute 
and eluents were monitored at 230 nm using UV/VIS detector. The method was validated for linearity, 
precision, accuracy, reproducibility, limit of detection (LOD) and limit of quantification (LOQ). Linearity 
for haloperidol was in the range of 1-16 µg/mL. The value of LOD and LOQ was found to be 0.045 
and 0.135 μg/mL respectively. The shelf life of SLNs formulation was found to be 2.31 years at 4 oC. 
Various parameters like drug targeting index (DTI), drug targeting efficiency (DTE) and nose-to-brain 
direct transport (DTP) were determined for HP-SLNs & HP-Sol administered intranasally to evaluate 
the extent of nose-to-brain delivery. The value of DTI, DTE and DTP for HP-SLNs was found to be 
23.62, 2362.43 % and 95.77% while for HP-Sol, values were 11.28, 1128.61 % and 91.14 % respectively.
Uniterms: Haloperidol/quantification. Haloperidol/pharmacokinetic. Haloperidol/in vitro study. 
Haloperidol/in vivo study. High performance liquid chromatography/solid lipid nanoparticles. Plasma. 
Validation. Brain targeting.
INTRODUCTION
Haloperidol is an orally administered dopamine 
inverse agonist of the typical antipsychotic class of 
medication that chemically belongs to butyrophenone 
group (Gajski, Geri, Garaj-Vrhovac, 2014). Its mechanism 
of action is mediated by blockade of D2 dopamine receptors 
in brain (Benvegnú et al., 2011). Haloperidol is used to treat 
certain psychiatric conditions including schizophrenia, 
maniac states, medicament induced psychosis and 
neurological disorders with hyperkinesias (Forsman, 
1976). Haloperidol is chemically 4-[4-(4-chlorophenyl)-
4-hydroxypiperidino] 4’- fluorobutyrophenone (Figure 1). 
The molecular formula of haloperidol is C21H23ClFNO2 and 
molecular weight is 375.86 g/mol.
Various analytical techniques have been used 
for determination of haloperidol in pharmaceutical 
formulations. These include high performance liquid 
chromatography (HPLC) (Wate, Borkar, 2009), high 
performance thin-layer chromatography (HPTLC) (Sigrid 
et al., 2007), 19F NMR spectroscopy (Mojtaba et al., 
2007), square-wave adsorptive stripping voltammetry 
FIGURE 1 - Structure of haloperidol.
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at a mercury electrode (El-Desoky, Ghoneim, 2005), 
square-wave and cyclic voltammetry at hanging mercury 
drop electrode (Ribeiro et al., 2011), cyclic voltammetry 
at multi-walled carbon nanotubes-modified glassy 
carbon electrode (Huang et al., 2008). Non-aqueous 
titrimetric method has also been developed for haloperidol 
determination in pharmaceutical preparations (European 
Pharmacopoeia, 2002). UV spectrophotometric assay 
procedures have been developed and described in official 
compendia (Janicki, Ko, 1991; Chinese Pharmacopoeia, 
2005; Yasir, Sara, 2014a). The analytical procedures 
like HPLC technique are still being frequently used and 
published. 
The aim of present study was to develop and validate 
a new HPLC method for the quantitative analysis of 
haloperidol in SLNs. The different analytical performance 
parameters such as linearity, precision, accuracy, 
reproducibility, limit of detection (LOD) and limit of 
quantification (LOQ) were determined according to ICH 
Q2 (R1) guidelines (ICH, 2005; Dalila et al., 2012). For 
the determination of pharmacokinetic and brain targeting 
parameters after intranasal administration of haloperidol 
loaded solid lipid nanoparticles (HP-SLNs) and plain drug 
solution (HP-Sol), the calibration curve of haloperidol in 
rat plasma was prepared by the reported RP-HPLC method 
(Jain et al., 2011). 
MATERIAL AND METHODS
Chemicals
Haloperidol was received as a gift sample from 
Vamsi Labs Ltd Solapur, Maharashtra, India. Potassium 
dihydrogen phosphate was purchased from Qualigens fine 
chemicals, Mumbai, India. Sodium hydroxide was procured 
from Fisher scientific, Mumbai, India. Acetonitrile 
(ACN), Triethylamine (TEA) and o-phosphoric acid were 
purchased from Sigma-Aldrich, New Delhi, India. All 
reagents were of HPLC grade. Milli-Q grade (Millipore, 
Molsheim, France) water was used to prepare solutions 
wherever required and it was filtered before use through 
a 0.22 µm membrane filter. 
Instruments
Bath sonicator (Multitech Pvt. Ltd., N. Delhi), 
Balance (AUX 220, Shimadzu Corporation, Kyoto, 
Japan), Magnetic stirrer (Remi Instruments Pvt. Ltd., 
Mumbai, India), pH meter (Hicon Scientific Instruments, 
Delhi, India), Centrifuge (Remi Instruments Pvt. Ltd., 
India), Micro pipettes (Labnet, USA), Vortex mixer 
(S.M. Scientific instruments Pvt. Ltd, Delhi) were used 
for the study.
HPLC System: Jasco HPLC system was used with 
following specifications
Column: C-18 Cosmosil packed column 
             (5 C18- MS-II, 250 mm x 4.6 mm x 5.0 μm)
Pump: Jasco PU- 2080 plus
Type of Pump: Isocratic type 
Detector: UV/VIS detector (Jasco UV 2075 plus)
Software: Jasco Borwin version (1.5, LC-Net II/ADC 
system)
Injector: Syringe type manual injector
Injection Vol.: 20 µL
Other accessories for HPLC embodies HiMedia 
Syringe-driven filters of 0.22 μm pore size
HPLC method
Several  methods have been developed for 
the determination of haloperidol in pharmaceutical 
preparation. 
The concentration of haloperidol had been earlier 
determined by HPLC method using methanol-water 
(63:37, v/v) containing 0.2 M ammonium acetate as 
mobile phase and diphenylamine as internal standard (IS) 
(Miyazaki et al., 1981). The method used here was 
slightly modified in the terms of mobile phase.100 mM/L 
potassium dihydrogen phosphate–acetonitrile–TEA 
(10:90:0.1, v/v/v) was used as mobile phase and the pH was 
adjusted with o-phosphoric acid to 3.5. It was sonicated 
for 15 minutes and filtered through 0.22 μm membrane 
filter. Flow rate of mobile phase was maintained at 2 mL/
min and eluents were monitored at 230 nm. The samples 
(20 μL ) were injected using manual type HPLC injector. 
All determinations were performed at ambient temperature 
for a run time of 5 min. 
Preparation of calibration curve
A stock solution of 1.0 mg/mL of haloperidol was 
prepared in mobile phase. An appropriate volume of stock 
solution was further diluted with mobile phase to obtain 
a standard solution having a final concentration 100 μg/
mL. Different concentrations (1-16 μg/mL) were made 
for the preparation of calibration curve from the prepared 
standard solution. The prepared dilutions were injected 
serially (20 μL) and area under peak was recorded for 
each dilution. The calibration curve was constructed by 
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plotting the concentration of haloperidol on X -axis and 
peak area on Y-axis. 
Method validation
HPLC method for Haloperidol was validated as 
per the ICH guidelines Q2 (R1) for linearity, precision, 
accuracy, reproducibility , LOD and LOQ.
Linearity
The linearity of response for haloperidol was 
assessed in the range of 1-16 µg/mL for standard drug.
Accuracy as recovery
Accuracy was determined using standard addition 
method. The pre-analyzed samples were spiked with 
extra 50, 100 and 150 % of the standard haloperidol and 
the mixtures were analyzed by the proposed method. The 
experiment was performed in triplicate. The % recovery, 
% relative standard deviation (RSD), and standard error 
of mean (SEM) were calculated at each concentration 
level. 
Precision
The precision was determined at two levels as per 
ICH, Q2 (R1) guidelines i.e. repeatability and intermediate 
precision. 
a. Repeatability: Repeatability of drug sample 
was determined as intraday variation. Three replicates 
for each of the three concentrations were analyzed three 
times a day. Hence a minimum of 9 determinations were 
performed covering the specified range for the procedure. 
The % relative standard deviation was calculated for area 
to obtain the intraday variation
b. Intermediate precision: It was determined 
by interday variation (for three different days) for 
the determination of haloperidol at three different 
concentration levels of 4, 8 and 12 µg/mL in triplicate. 
The % relative standard deviation was calculated for area 
to obtain the interday variation.
Reproducibility
Reproducibility of the method was investigated by 
obtaining precision of the method in another laboratory 
using the different instrument and analyzed by another 
person. Both intraday & interday precision were calculated 
at three different concentration levels of 4,8,12 μg/ mL. 
LOD and LOQ determination
LOD and LOQ of the drug were calculated as per 
ICH Q2 (R1) guidelines (ICH, 2005) using the standard 
deviation method with the help of equations 1 and 2 
respectively.
 LOD = 3.3 × s/S (1)
 LOQ = 10 × s/S (2)
where σ = standard deviation of the response; S= slope of 
the regression line.
Application of developed HPLC method for In 
vitro studies i.e. in determination of shelf life
Haloperidol loaded solid lipid nanoparticles (HP-
SLNs) were prepared by modified solvent emulsification–
diffusion technique (Kumar et al., 2013) and optimised 
by Boxbehken design (Yasir, Sara, 2013). The shelf life 
of optimized HP-SLNs was determined by conventional 
method using Arrhenius equation. Optimized SLN 
formulations were kept at 25 ± 2 ºC; 30 ±2 ºC and 40 ± 
2 ºC at ambient RH (Shakeel et al., 2007). Samples were 
withdrawn after specified time intervals (0, 30, 90, and 
180 days) and the drug content was determined using 
HPLC. Amount of drug remaining was determined at each 
interval. Logarithm of percent drug remaining versus time 
(days) was plotted. The degradation rate constant ‘K’ was 
determined from the slope of the lines at each elevated 
temperature using the following equation (3).
  (3)
Arrhenius Plot was constructed between log K and 
1/T to determine the shelf life of optimized SLNs. K value 
at 4 oC was determined using extrapolation method. The 
shelf life (T0.9) at 4 oC was calculated with the help of 
following equation (4).
  (4)
HPLC method in rat plasma for in vivo studies
For in vivo studies, the calibration curve of 
haloperidol in rat plasma was prepared by the reported 
RP-HPLC method (Jain et al., 2011).
Preparation of stock solution
A stock solution (1.0 mg/mL) of drug was prepared 
in mobile phase. Aliquots from stock solution were 
further diluted with mobile phase to yield a standard 
solution of drug having a final concentration of 1 μg/mL. 
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Different concentrations (20 -90 ng/mL) were made for 
the preparation of calibration curve from the final standard 
solution. 
Preparation of calibration curve for determination of 
haloperidol in rat plasma
Calibration curve was prepared by adding known 
amount of haloperidol (20, 30, 40, 50, 60, 70, 80 and 90 
ng/mL) to 1 ml of blank plasma in test tube separately. 
An aliquot (500 μL) of loratidine solution (internal 
standard, concentration 100 ng/mL) was added in each 
test tube separately. Each test tube was vortexed by 
adding 5 mL isopropyl alcohol for 5 min on a vortex 
mixer (S.M. Scientific instruments Pvt. Ltd, Delhi) and 
then centrifuged at 4000 rpm for 10 min until a clear 
organic layer was separated. Organic layer was evaporated 
to dryness at room temperature. Subsequently dried 
sample was reconstituted with 0.3 ml mobile phase and 
evaluated by HPLC for the presence of haloperidol. The 
calibration curve was constructed between concentration 
of haloperidol (X-axis) and peak area ratio of haloperidol 
and loratidine (Y-axis).
In vivo studies for the determination of 
pharmacokinetic and Brain targeting parameters 
Comparative in vivo studies were performed for both 
haloperidol solution (positive control) (HP-Sol) and HP-
loaded SLNs administered intranasally (i.n.) and HP-Sol 
(positive control) administered intravenously (i.v.). 
Animals for in vivo study
In vivo studies were performed on male albino 
wistar rats (Adult/weighing 200-250 g). A protocol for 
animal studies was approved by Institutional animal 
ethical committee and project number was ITS/03/
IACE/2013. The animals were kept under standard 
laboratory conditions i.e. temperature of 22 ± 3 °C and 
relative humidity of 30%-70%. The animals were housed 
in polypropylene cages, (6 animals per cage) with free 
access to standard laboratory diet and water ad libitum. 
Calculation of dose for rats
Dose for the rats was calculated taking into 
consideration ratio of surface area of a rat to that of a 
human being (Yasir, Sara, 2014b). Surface area ratio for a 
rat (200 g) to a human (70 kg) is 56. Dose for 200 g rat can 
be calculated by following equation (5).
  (5)
where x is the dose of rat per 200 g. The dose of haloperidol 
for human is 10 mg. Hence x =0.179 mg per 200 g of rat 
i.e. 0.893 mg/kg.
In vivo study 
For in vivo study, Rats were divided in three different 
groups: 
Group A, positive control for intravenous (i.v.) drug ad-
ministration (HP-Sol); 
Group B, positive control for intranasal (i.n.) drug admin-
istration (HP-Sol); and 
Group C, intranasal (i.n.) formulation administration 
(HP-SLNs). 
Each group was divided into 8 subgroups (containing 6 
animals) on time basis as given below:
Subgroup 1: drug was administered at time 0 and sacrifice 
was done after 0.167 h
Subgroup 2: drug was administered at time 0 and sacrifice 
was done after 0.5 h
Subgroup 3: drug was administered at time 0 and sacrifice 
was done after 1 h
Subgroup 4: drug was administered at time 0 and sacrifice 
was done after 2 h
Subgroup 5: drug was administered at time 0 and sacrifice 
was done after 4 h
Subgroup 6: drug was administered at time 0 and sacrifice 
was done after 6 h
Subgroup 7: drug was administered at time 0 and sacrifice 
was done after 8 h
Subgroup 8: drug was administered at time 0 and sacrifice 
was done after 24 h
Procedure of drug administration
Drug solution (positive control), containing 
0.179 mg (for rat weighing 200 g) of haloperidol 
(equivalent to 0.89 mg/kg body weight), was injected 
through the tail vein (10 µL) in one group of rats. 
Similarly, drug solution and drug formulation (HP-SLNs) 
containing 0.179 mg of haloperidol were administered 
in each nostril in the other two groups with the help of 
micropipette (10-100 µL) with 0.1 mm internal diameter 
at the delivery site. The rats were anaesthetized prior 
to nasal administration by pentobarbital sodium 
(35-50 mg/kg, i.p.) and held firmly from the back in a 
slanted position during nasal administration. 
Procedure for blood sampling
The rats were killed humanely by overdose of 
pentobarbital sodium at different time intervals (0.167, 0.5, 
1, 2, 4, 6, 8 and 24 h) and the blood was collected using 
cardiac puncture in EDTA coated Eppendrof tubes. The 
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blood was centrifuged at 4000 rpm for 20 min and aliquots 
of the supernatant separated and stored at -21 °C until drug 
analysis was carried out using HPLC (Kumar et al., 2008). 
At the same interval of blood collection, the rats 
were sacrificed to separate the brain. Brain was rinsed 
twice with normal saline, made free from adhering tissue/
fluid and weighed. Cold normal saline solution was 
added (brain weight: normal saline, 1:5) to the brain and 
homogenized on ice. The homogenate was centrifuged 
at 4000 rpm for 20 min at 4 °C, and aliquots of the 
supernatant were separated and stored at –21 °C until 
drug analysis was carried out using HPLC (Haque et al., 
2014).
Procedure of drug extraction from plasma by liquid- 
liquid extraction method
Chromatographic separation was achieved with a 
Cosmosil C18 column (250 mm × 4.6 mm, particle size 5 
µm). The mobile phase consisted of 100 mmol/L potassium 
dihydrogen phosphate–acetonitrile–TEA (10:90:0.1, v/v/v) 
and the pH was adjusted with o-phosphoric acid to 3.5. 
The mobile phase was sonicated for 15 min and filtered 
through 0.22 μm membrane filter before using. Flow rate 
of mobile phase was maintained at 2 mL/min and eluents 
were monitored at 230 nm. Twenty μL of sample was 
injected using a HPLC injector. All determinations were 
performed at ambient temperature for a run time of 5 min.
The extraction of haloperidol from plasma and brain 
samples was carried out using the liquid–liquid extraction 
(LLE) technique. Plasma sample and homogenized 
brain tissue (0.5 mL) was mixed with 100 µL loratidine 
(100 ng/mL) as internal standard solution (Jain et al., 
2011; Rahman, Khatoon, Rahman, 2012). The mixture 
was shaken with 2 mL isopropyl alcohol for 2 min on a 
vortex mixer and then centrifuged at 4000 rpm for 10 min 
until a clear organic layer was separated. Organic layer 
was evaporated to dryness under nitrogen gas at room 
temperature. Dried sample was then reconstituted with 
0.3 mL mobile phase and evaluated by HPLC for the 
presence of drug. 
Analysis of pharmacokinetic and brain targeting 
parameters
P l a s m a  c o n c e n t r a t i o n – t i m e  p r o f i l e s  o f 
haloperidol after i.n. and i.v. delivery were evaluated by 
pharmacokinetic software (PK Functions for Microsoft 
Excel, Pharsight Corporation, Mountain View, CA, USA). 
Various pharmacokinetic parameters as Cmax, Tmax, AUC0-
∞ and elimination rate constant (Ke) were calculated. 
Statistical analysis was performed using Graph pad prism 
5.0 (Graph pad software San Diego, CA). All results were 
expressed as mean ± SD. Difference among the groups 
was compared with the analysis of variance (ANOVA) 
followed by Tukey-Kramer multiple comparison test. P- 
Value < 0.05 was considered statistically significant. The 
extent of nose-to-brain delivery could be evaluated by 
many parameters (Abdelbeary, Tadros, 2013): 
(i) The brain/blood ratio, at 0.5 h, following intrana-
sal and intravenous administration (Vyas et al., 
2005). 
(ii) The relative bioavailability (RB) percentages fol-
lowing the intranasal administration in the blood 
and brain (MD et al., 2012). 
(iii) The drug targeting index (DTI) (Wang, Jiang, Lu, 
2003). 
(iv) The drug targeting efficiency (DTE) percentage 
(Chow, Chen, Matsuura, 1999). 
(v) The nose-to-brain direct transport percentage (DTP) 
(Zhang et al., 2004, Wang, Chi, Tang, 2008). 
The relative bioavailability (%) of the intranasal 
HP-SLNs formulation to intranasal HP-Sol was determined 
according to following equation (6).
  (6)
The DTI can be described as the ratio of the AUC 
brain/AUC blood following i.n. administration to that 
following i.v. administration. Following equation (7) was 
used for the determination of DTI.
  (7)
The percent brain targeting efficiency (DTE %) and 
nose to brain direct transport percentage (DTP %) were 
calculated with the help of given equation (8 & 9) (Wang, 
Jiang, Lu, 2003; Abdelbary, Tadros, 2013).
  (8)
  (9)
where F = (AUC0–24, brain, i.v. / AUC0–24, blood, i.v.) × AUC0–24, 
blood, i.n., AUC0–24, brain, i.n. is the area under the curve of brain 
following i.n. administration, AUC0–24, brain, i.v. is the area 
under the curve of brain following i.v. administration, 
AUC0–24 blood, i.v. is the area under the curve of blood 
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following i.v. administration, AUC0–24 blood, i.n. is the area 
under the curve of blood following i.n. administration.
RESULTS AND DISCUSSION
Preparation of calibration curve
Calibration curve was constructed and a linear 
relationship was observed between peak area and 
concentration. The regression data for calibration curve 
showed a good linear relationship over concentration 
range of 1-16 µg/mL with respect to the peak area 
(Figure 2). The retention time of haloperidol was found 
to be 2.758±0.12 min as shown in Figure 3.
Method validation
Using the optimized chromatographic conditions, 
the developed HPLC method was validated with respect 
to linearity, precision, accuracy, reproducibility, LOD and 
LOQ as per the ICH guidelines.
Linearity
The linearity range of haloperidol solution was 
obtained as 1-16 µg/mL. The linear regression equation 
was found to be Y = 101563X + 7043.1 with correlation 
coefficient (R2) of 0.9995.
Accuracy as recovery studies
The proposed method afforded recovery of 99.55-
100.42% after spiking the additional standard drug 
solution to the previously analyzed test solution. The value 
of % recovery, % RSDs and SE are shown in Table I, which 
indicated the accuracy of the proposed method.
Precision
The precision was assessed by analyzing haloperidol 
in three different concentration levels as 4, 8 and 12 μg/
ml of in triplicate. The results of repeatability (intraday 
precision) and intermediate (interday) precision were 
expressed in the terms of % RSD. The intraday and 
interday precision study of the developed method 
confirmed the adequate sample stability and method 
reliability where all RSDs were below 2% as shown in 
Table II.
Reproducibility
Reproducibility of the method was investigated by 
obtaining precision of the method in another laboratory 
using the different instrumentation and analysis being 
performed by another person. Both intraday & interday 
precision were calculated and no significant differences 
were observed (P< 0.05) in the % RSD values of intraday 
and interday precision, which indicated the reproducibility 
of the method. The results of intraday and interday 
precision are shown in Table III.
LOD and LOQ determination
LOD and LOQ of this method were determined by 
the standard deviation method. The value of LOD and 
LOQ were found to be 0.045 and 0.135 μg/ml respectively, 
which signifies that proposed method can be used for the 
detection and quantification of haloperidol even in very 
low concentration. 
Application of Developed HPLC method for in 
vitro studies i.e. in determination of shelf life
The percentage drug remaining in the optimized 
formulation (HP-SLNs) when stored for 180 days at 
elevated temperatures of 25±2 ºC; 30 ± 2 ºC; and 40±2 ºC 
at ambient RH was determined by HPLC method 
(Table IV). Figure 4a depicts the graph obtained by 
plotting Logarithm of percent drug remaining versus time 
(days). The degradation rate constant ‘K’ was determined 
FIGURE 2 - Calibration curve of haloperidol by HPLC method.
FIGURE 3 - HPLC chromatogram of haloperidol.
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from the slope of the lines at each elevated temperature 
using the equation (3). 
Arrhenius plot was constructed between log K and 
1/T (Table V and Figure 4b). From the plot, the value 
of degradation rate constant (K4) at 4ºC (refrigerator 
temperature) was determined. Shelf life was calculated by 
placing the value of K4 in equation (4). The shelf life of HP 
in SLNs at 4ºC was found to be 2.31 years. The degradation 
kinetics of HP in SLNs was also determined and it was 
found to be first order kinetics as shown in Figure 4a.
TABLE I - Accuracy as recovery of proposed method
% of standard 
spiked to the 
sample
Concentration
% drug 
recovered % RSD SESample 
(μg /mL)
Total including 
spiked sample  
(μg /mL)
Spiked sample 
determined 
(μg /mL) ± SD 
(n = 3) 
50 10 15 15.03±0.29 99.55 1.93 0.17
100 10 20 19.97±0.21 99.86 1.03 0.12
150 10 25 25.11±0.35 100.42 1.39 0.20
TABLE II - Precision of proposed method
Conc. 
(μg/ mL)
Repeatability (intraday precision) Intermediate precision (interday)
Mean area ± SD 
(n=3) 
SEM % RSD Days Mean area ± SD 
(n=3)
SEM % RSD
4 424842± 2410 1393 0.56 1 425363±3293 1903 0.77
2 422999±5335 3084 1.26
3 420934±3868 2236 0.91
8 835070±9054 5234 1.08 1 840698±5981 3457 0.71
2 839759±4031 2330 0.48
3 836843±3414 1973 0.41
12 1256774±11926 6894 0.95 1 1249711±12335 7130 0.99
2 1251832±13451 7775 1.1
3 1246394±13045 7540 1.05
TABLE III - Reproducibility of proposed method
Conc. 
(μg/ mL)
Repeatability (intraday precision) Intermediate precision (interday)
Mean area ± SD 
(n=3) 
SEM % RSD Days Mean area ± SD 
(n=3)
SEM % RSD
4 421175±5048 2918 1.19 1 424363±7371 4261 1.74
2 417599±6567 3796 1.57
3 425268±5608 3241 1.32
8 836737±11564 6684 1.38 1 838365±10388 6004 1.24
2 837659±8401 4856 1.00
3 834843±12296 7108 1.47
12 1253774±14150 8179 1.12 1 1250378±16891 9763 1.35
2 1253832±11973 6920 0.95
3 1248394±9806 5668. 0.79
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HPLC method in rat plasma for in vivo studies
For in vivo studies, the calibration curve of 
haloperidol in rat plasma was prepared by the reported 
RP-HPLC method (Jain et al., 2011).
Preparation of calibration curve for determination of 
haloperidol in rat plasma
Calibration curve was prepared in rat plasma by the 
reported RP-HPLC method (Jain et al., 2011). Calibration 
curve was obtained by plotting the peak area ratio of 
haloperidol to internal standard against the respective 
concentration (Figure 5). The linearity was observed 
in concentration range of 20-90 ng/ml. The HPLC 
chromatogram of plasma spiked with haloperidol and 
blank plasma are shown in Figure 6a and 6b respectively. 
The approximate retention time of haloperidol and IS was 
found to be 2.536 and 3.59 min respectively.
Drug extraction from plasma by liquid- liquid 
extraction method
Liquid- liquid extraction method as described above 
was used for the drug extraction from rat plasma. Isopropyl 
alcohol was used as extraction solvent to obtain better 
recovery and good separation from the plasma impurities. 
The mobile phase was a mixture of 100 mM potassium 
dihydrogen phosphate, acetonitrile and TEA (10:90:0.1, 
v/v/v) and the pH was adjusted with o-phosphoric acid to 
3.5. Loratidine was chosen as internal standard because it 
showed similar chromatographic behaviour to haloperidol 
with no interference. A satisfactory peak resolution and 
reasonable retention of the drug and internal standard 
were obtained. 
In vivo studies for the determination of 
pharmacokinetic & brain targeting parameters 
The haloperidol concentrations in brain following 
TABLE IV - Degradation of optimized HP- SLNs kept at 25±2 ºC; 30±2 ºC and 40±2 ºC at ambient RH
Storage condition (oC) Sampling interval (days) % drug remaining Log % drug remaining
25±2 0 100 2
30 99.6 1.9983
90 98.65 1.9942
180 97.51 1.989
30±2 0 100 2
30 99.26 1.9968
90 98.23 1.9923
180 97.13 1.9874
40±2 0 100 2
30 99.01 1.9957
90 97.66 1.9917
180 96.49 1.9845
FIGURE 4 - (a) Log % drug remaining vs. time plot (b) Arrhenius 
plot for optimized HP-SLNs formulation.
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the i.n. administration of HP-SLNs were found to be 
significantly (P<0.05) higher at all the time points as 
compared to both HP-Sol i.n. and HP-Sol i.v. (Figure 7a). 
The HP concentration in plasma following the i.n. 
of HP-SLNs were found to be significantly (P<0.05) 
lower at all the time points compared to HP-Sol i.v. 
administration (Figure 7b). Various pharmacokinetic 
parameters of haloperidol were determined as shown 
in Table VI. The lower value of Tmax for brain (2 h) as 
compared to blood (4 h) may attribute to the preferential 
nose to brain transport following i.n. administration. 
The value of Cmax (329.17±20.89 ng/mL) for brain 
after intranasal administration of HP-SLNs was 
significantly (P<0.05) higher than HP-Sol administered 
intranasally and intravenously. Similarly, the value of 
AUC0-∞ (2389.17±78.82 ng.h/mL) of HP-SLNs i.n. 
was found to be significantly (P<0.05) higher than 
HP-Sol (i.n. and i.v.). This might be due to the direct 
transport of drug through olfactory route by bypassing 
the BBB. 
As reported by Dhuria, Hanson and Frey (2010), 
the drug uptake by brain from the nasal mucosa can 
be achieved via three major pathways (i) a systemic 
pathway of drug absorption into the blood circulation 
which subsequently reaches to the brain across the 
BBB, (ii) lymphatic pathway (Abdelbary, Tadros, 2013) 
(iii) a direct pathway from nasal mucosa epithelium into 
brain mainly along olfactory or trigeminal nerves by 
passing the BBB (MD et al., 2012). The extent of nose-
to-brain delivery could be evaluated by the following 
parameters. 
a) The brain/blood ratio, at 0.5 h, following intra-
nasal and intravenous administration: This value 
was found to be 1.61, 0.17 and 0.03 for HP-SLNs 
i.n., HP-Sol i.n. and HP-Sol i.v. respectively (Table 
TABLE V - Various parameters for calculation of shelf life 
Temperature 
(ºC)
Temperature 
(ºK)
(1/ T) × 10-3 
(ºK-1) Slope × 10 
-5 K × 10-4 Log K
25 298 3.355704 -7.1667 1.6505 -3.78239
30 303 3.30033 -7.5 1.7273 -3.76264
40 308 3.246753 -6.6667 1.5353 -3.8138
4 277 3.610183 --- 1.2496 -3.9032
FIGURE 5 - Calibration curve of HP in rat plasma by HPLC 
method.
FIGURE 6 - HPLC chromatogram in (a) plasma spiked with drug 
and IS (b) blank plasma.
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VII). A noteworthy high brain/blood ratio of HP-
SLNs could indicate the brain targeting potential of 
developed SLNs. The HP-Sol also reached directly 
in brain to some extent but significantly less than 
HP-SLNs and it could be due to lipophilic nature of 
haloperidol (log p approximately 4). Similar findings 
were observed by Kumar et al. (2008).
b) Compared to HP-Sol administered intranasally, 
the percent relative bioavailability of intranasal 
HP-SLNs, were found to be 155.32±11.83 and 
349.72±26.13 in blood and brain respectively (Table 
VI). The results revealed a significant (P<0.05) en-
hancement in the bioavailability of haloperidol in the 
brain following the intranasal administration of HP-
SLNs. These findings are in line with Abdelbary and 
Tadrosd (2013) who found that micellar nanocarriers 
increase the relatively bioavailability of olanzapine 
administered intranasally. 
c) The DTI, DTE (%) and DTP (%) values were esti-
mated to represent the percentage of drug directly 
transported to the brain via the olfactory or trigemi-
nal pathway. The value of DTI, DTE & DTP for 
HP-SLNs administered intranasally was found to 
be 23.62, 2362.43 % & 95.77%. While the value 
of DTI, DTE and DTP for HP-Sol administered 
intranasally was found to be 11.28, 1128.61% and 
91.14% respectively (Table VII). The DTI values >1 
could confirm the direct pathway from nose to brain 
(Wang, Jiang, Lu, 2003). These findings are in line 
with Jain et al. (2010), Kanazawa et al. (2011) who 
found that micellar nanocarriers of zolmitriptan and 
coumarin increase the nose-to-brain uptake, via the 
olfactory region of the nasal cavity. Finally, the high-
er value of DTI, DTE (%) and DTP (%) suggested 
that HP-SLNs have better brain targeting potential 
as compared to HP-Sol administered intranasally. 
Similar findings have also been reported previously 
by Zhang et al. (2004).
CONCLUSION
A new and simple HPLC method for haloperidol 
was developed and validated over the concentration 
range from 1-16 µg/mL. The method was successfully 
applied for the determination of haloperidol content in 
SLNs. Calibration curve was also prepared in rat plasma 
TABLE VI - Pharmacokinetic parameters of haloperidol in brain and plasma
P’kinetic 
parameters
Type of formulation/route of administration
HP-SLN i.n.* HP-Sol i.n.# HP-Sol i.v.
Brain Plasma Brain Plasma Brain Plasma
Cmax(ng/mL) 329.17 ± 20.89 393.5 ± 24.63 90.13 ± 6.28 306.96 ± 13.47 76.95 ± 7.62 2190 ± 60.67
Tmax (h) 2 4 2 1 1 0.167
Ke (h-1) 0.079 ± 0.0065 0.097 ± 0.003 0.077 ± 0.005 0.11 ± 0.003 0.095 ± 0.003 0.15 ± 0.007
AUC0-24 h (ng∙h/mL) 2172.33 ± 60.41 2433.05 ± 18.54 623.16 ± 8.51 1460.71 ± 15.67 433.65 ± 15.46 11464.59 ± 150.45
AUC0-∞ (ng∙h/mL) 2389.17 ± 78.82 2612.31 ± 40.67 683.15 ± 30.17 1681.82 ± 32.83 500.82 ± 12.78 12017.5 ±180.87
Values are mean ± SD, n=6 *𝑃 ˂  0.05 versus HP-Sol i.n., *𝑃 ˂  0.05 versus HP-Sol i.v., #P< 0.05 versus HP-Sol i.v., P< 0.05 results are significant
FIGURE 7 - Haloperidol concentration in (a) rat brain (b) rat 
plasma at different time intervals following HP-SLNs i.n., 
HP-Sol i.n. and HP-Sol i.v. administration.
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for determination of drug quantitatively. Satisfactory 
results were obtained, which signifies the reproducibility, 
sensitivity and reliability of method. 
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AUC0-∞ Area under the curve from time 0 to time 
infinity
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DTP Direct transport percentage 
HP  Haloperidol 
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RB Relative bioavailability
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